Is there a future for tigecycline?

Bassetti, Matteo; Poulakou, Garyfallia; Giamarellou, Helen

doi:10.1007/s00134-014-3343-3

Cited by 19 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However in the present study, there was no significant difference in clinical success or in mortality between patients who underwent monotherapy and those who underwent combination therapy. This is not in accordance with the most recent published reports on tigecycline use in adults for infections caused by MDR bacteria or under extremely critical clinical conditions (Bassetti et al, 2014;Mouloudi et al, 2014;Rodriguez et al, 2007).…”

Section: Discussioncontrasting

confidence: 95%

“…Tigecycline was introduced in China in 2011. Tigecycline is approved for the treatment of complicated intra-abdominal infections (cIAI), complicated skin and soft tissue infections (cSSTI), and community-acquired pneumonia in adults, but is not approved for use in those under the age of 18 years (Bassetti et al, 2014). US Food and Drug Administration (US FDA) warnings, connecting tigecycline with all-cause mortality, are of concern.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery

Song

Shu

et al. 2018

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery

Song

Shu

et al. 2018

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…According to the FDA, TGC is not recommended unless alternative treatment is not available. However, off‐label use of TGC is widely adopted in critically ill adults, especially for infections caused by MDR/XDR pathogen . In real‐world clinical practice, successful cases are also reported for off‐label use of TGC in children, especially for infections caused by MDR/XDR bacteria .…”

Section: Discussionmentioning

confidence: 99%

“…However, off-label use of TGC is widely adopted in critically ill adults, especially for infections caused by MDR/XDR pathogen. 9,10 In real-world clinical practice, successful cases are also reported for off-label use of TGC in children, especially TA B L E 2 Susceptibility testing results of K pneumoniae (n = 9) and A baumannii (n = 4) isolates to antimicrobial agents for infections caused by MDR/XDR bacteria. [11][12][13] Pediatricians usually prescribe TGC as salvage therapy in serious infections.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of tigecycline in the treatment of infections caused by carbapenem‐resistant gram‐negative bacteria in pediatric liver transplant recipients: A retrospective study

Chen

Shen

Pang

et al. 2019

Transplant Infectious Dis

View full text Add to dashboard Cite

Introduction Tigecycline (TGC) is effective for the infections caused by carbapenem‐resistant gram‐negative bacteria (CRGNB) in adults, but it is not investigated systematically in children because of concern about adverse effects. This study aimed to analyze the effectiveness of TGC in treating CRGNB infections in children after receiving liver transplant. Methods The subjects in this retrospective study were pediatric liver transplant recipients treated with TGC for at least 3 days to fight microbiologically verified CRGNB infection after initial antibiotic failure during the period from January 2014 to May 2018. Clinical and microbiological outcomes were reviewed to evaluate the efficacy and safety of TGC. Results Of the 1177 pediatric liver transplant recipients, 13 patients were eligible for inclusion in this analysis. All the patients received TGC at dose of 2 mg/kg every 12 hours for a duration of 10.1 ± 5.1 days on average to treat CRGNB infections, including complicated intra‐abdominal infection, ventilator‐associated pneumonia, and bloodstream infection. The isolates included Klebsiella pneumoniae (69.2%, 9/13) and Acinetobacter baumannii (30.8%, 4/13). Clinical efficacy was achieved in 84.6% (11/13) and pathogen eradicated in 69.2% (9/13) of the patients. The overall mortality rate was 15.4% (2/13). No TGC‐related serious adverse event was reported. Conclusion Tigecycline can be considered in combination antimicrobial regimen for treating CRGNB‐related infections in pediatric liver transplant recipients.

show abstract

Bio‐Responsive Sliver Peroxide‐Nanocarrier Serves as Broad‐Spectrum Metallo‐β‐lactamase Inhibitor for Combating Severe Pneumonia

Li,

Duan,

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Metallo‐β‐lactamases (MBLs) represent a prevalent resistance mechanism in Gram‐negative bacteria, rendering last‐line carbapenem‐related antibiotics ineffective. Here, a bioresponsive sliver peroxide (Ag2O2)‐based nanovesicle, named Ag2O2@BP‐MT@MM, is developed as a broad‐spectrum MBL inhibitor for combating MBL‐producing bacterial pneumonia. Ag2O2 nanoparticle is first orderly modified with bovine serum albumin and polydopamine to co‐load meropenem (MER) and [5‐(p‐fluorophenyl)‐2‐ureido]‐thiophene‐3‐carboxamide (TPCA‐1) and then encapsulated with macrophage membrane (MM) aimed to target inflammatory lung tissue specifically. The resultant Ag2O2@BP‐MT@MM effectively abrogates MBL activity by displacing the Zn2+ cofactor in MBLs with Ag+ and displays potent bactericidal and anti‐inflammatory properties, specific targeting abilities, and great bioresponsive characteristics. After intravenous injection, the nanoparticles accumulate prominently at infection sites through MM‐mediated targeting . Ag+ released from Ag2O2 decomposition at the infection sites effectively inhibits MBL activity and overcomes the resistance of MBL‐producing bacteria to MER, resulting in synergistic elimination of bacteria in conjunction with MER. In two murine infection models of NDM‐1+ Klebsiella pneumoniae‐induced severe pneumonia and NDM‐1+ Escherichia coli‐induced sepsis‐related bacterial pneumonia, the nanoparticles significantly reduce bacterial loading, pro‐inflammatory cytokine levels locally and systemically, and the recruitment and activation of neutrophils and macrophages. This innovative approach presents a promising new strategy for combating infections caused by MBL‐producing carbapenem‐resistant bacteria.

show abstract

Is there a future for tigecycline?

Cited by 19 publications

References 35 publications

Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery

Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery

Effectiveness of tigecycline in the treatment of infections caused by carbapenem‐resistant gram‐negative bacteria in pediatric liver transplant recipients: A retrospective study

Bio‐Responsive Sliver Peroxide‐Nanocarrier Serves as Broad‐Spectrum Metallo‐β‐lactamase Inhibitor for Combating Severe Pneumonia

Contact Info

Product

Resources

About